Valuation: Galapagos NV

Market Cap 154.73Cr 178.03Cr 144.45Cr 132.61Cr 250.05Cr 17TCr 254.41Cr 1.7TCr 667.1Cr 8.46TCr 668.72Cr 653.91Cr 28TCr P/E 2026 *
-11x
P/E 2027 * -8.31x
Enterprise Value -44Cr -50Cr -41Cr -37Cr -70Cr -4.78TCr -72Cr -479.98Cr -187.98Cr -2.38TCr -188.44Cr -184.27Cr -7.87TCr EV / Sales 2026 *
-30.6x
EV / Sales 2027 * -9.68x
Free-Float
74.64%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 53 12/05/2025
Director of Finance/CFO 41 07/07/2025
Chief Operating Officer - 01/06/2026
Director TitleAgeSince
Director/Board Member 63 22/10/2019
Director/Board Member 49 07/10/2024
Director/Board Member 53 12/05/2025
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00% - - 178.03Cr
+0.66%+0.14%-2.06%+14.33% 4.82TCr
-2.71%-2.99%+398.09%+472.12% 3.88TCr
-0.71%+9.45%+27.90%+7.89% 3.84TCr
-0.71%-3.72%+4.94%+52.45% 3.49TCr
-2.41%+1.96%+11.68%+38.17% 2.92TCr
-0.66%-2.73%+35.50%+122.17% 1.6TCr
-0.19%-3.93% - - 1.6TCr
+0.35%-0.79%+2.16%+15.38% 1.35TCr
-3.15%-6.14%-4.82%-36.90% 1.22TCr
Average -0.96%-0.66%+59.17%+85.70% 2.75TCr
Weighted average by Cap. -0.98%+0.15%+75.53%+103.62%

Financials

2026 *2027 *
Net sales 1.42Cr 1.64Cr 1.33Cr 1.22Cr 2.3Cr 156.18Cr 2.34Cr 16Cr 6.14Cr 78Cr 6.15Cr 6.02Cr 256.89Cr 4.61Cr 5.3Cr 4.3Cr 3.95Cr 7.45Cr 505.45Cr 7.58Cr 51Cr 20Cr 252.06Cr 20Cr 19Cr 831.39Cr
Net income -81Cr -93Cr -76Cr -69Cr -131.01Cr -8.89TCr -133.3Cr -892.46Cr -349.53Cr -4.43TCr -350.38Cr -342.62Cr -15TCr -24Cr -27Cr -22Cr -20Cr -38Cr -2.61TCr -39Cr -261.78Cr -102.53Cr -1.3TCr -102.78Cr -100.5Cr -4.29TCr
Net Debt -198.33Cr -228.2Cr -185.16Cr -169.98Cr -320.51Cr -22TCr -326.1Cr -2.18TCr -855.08Cr -11TCr -857.16Cr -838.17Cr -36TCr -199.35Cr -229.38Cr -186.12Cr -170.86Cr -322.17Cr -22TCr -327.78Cr -2.19TCr -859.51Cr -11TCr -861.6Cr -842.51Cr -36TCr
Logo Galapagos NV
Lakefront Biotherapeutics NV (formerly Galapagos NV) is a biotechnology company built to bring meaningful medicines to patients with serious diseases in therapeutic areas of unmet need. The Company combines world-class deal making expertise with capital to identify, acquire, and advance promising opportunities that have the potential to drive value for patients and shareholders. Applying a modality-agnostic asset selection approach and operational flexibility, Lakefront Biotherapeutics NV prioritizes oncology and immunology & inflammation programs with clear clinical proof-of-concept in emerging areas.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B